Treats CMV retinitis. ANDA 200790, held by Strides Pharma Intl. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 200790 (Valganciclovir Hydrochloride), held by Strides Pharma Intl, was first approved by FDA on Nov 4, 2014, with 2 approved supplements and 0 published complete response letters.
Valganciclovir Tablets, USP are a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir Tablets, USP are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 4, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE · tablet;oral | Valganciclovir Hydrochloride | Rx |
| Mar 12, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 28, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 4, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters